ZG005 not checked

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
10 active
15 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Recommended Phase 2 Dose (RP2D) of ZG005(20 mg/kg), intravenous infusion, once every 3 weeks.”In the company’s words, NCT06927687 on ClinicalTrials.gov
Tested for
Advanced Solid Tumor (3 trials), Hepatocellular Carcinoma, Neuroendocrine Carcinomas (NEC), Biliary Tract Carcinoma, Lymphoma, Non-small Cell Lung Cancer, Cervical Cancer, Small Cell Lung Cancer and 1 more
Main trialPhase 3
“The purpose of the study is to evaluate the efficacy of ZG005 combined with bevacizumab compared with sintilimab combined with bevacizumab in the first-line treatment of participants with advanced HCC”In the company’s words, NCT07813572 on ClinicalTrials.gov

Other drugs for Advanced Solid Tumor

All 2440 drugs for Advanced Solid Tumor

Coming up10

Changes1

Last 90 days

Trials15

TrialPhaseCompletesWhat it tests
Phase 3Recruiting Sep 2031 ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular
Phase 3Not yet recruiting Oct 2031 ZG005 Plus Etoposide and Cisplatin vs. Etoposide and Cisplatin as First-Line Treatment for Advanced Neuroendocrine Carcinoma
Phase 2Active, not recruiting May 2027 Study of ZG005 in Patients With Advanced Solid Tumors
Phase 2Recruiting Dec 2027 Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract Carcinoma
Phase 1/2Recruiting Apr 2027 Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma
Phase 1/2Recruiting Apr 2027 Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer
Phase 1/2Recruiting May 2027 Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors
Phase 1/2Recruiting Aug 2027 Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer
Phase 1/2Recruiting Sep 2027 ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
Phase 1/2Not yet recruiting Oct 2027 Study of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid Tumors
Phase 2Unknown Sep 2026 Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma
Phase 1/2Unknown Mar 2026 A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor
Phase 1/2Unknown May 2026 Study of ZG005 in Combination With Paclitaxel+Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma
Phase 1/2Completed 22 Jul 2026 A Study of ZG005 in Patients With Advanced Solid Tumors
Phase 1/2Unknown Jul 2026 Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow ZG005

Following is part of Solo: you see every change to ZG005 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in